Company intelligence / Profile preview

Angiochem Inc.

Montreal, Quebec, Canadaorpha.net ↗

Ownership: Private
Development stage: Phase 3

Overview

ANG1005 (peptide-paclitaxel conjugate) is in Phase III clinical trials for brain metastasis associated with breast cancer. Previous Phase II trials showed promising signs of anti-tumor activity in HER2+ and HER2- breast cancer patients with brain metastasis. ANG4043 (peptide-mAb conjugate targeting HER2) has shown efficacy in preclinical studies, achieving therapeutic brain concentrations and increasing median survival time by 78% in mouse models.

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: Peptide drug conjugatessmall moleculesbiologics
Industry: Biotech

Drug pipeline

9 assets

paclitaxel trevatide

8 more assets in the full pipeline.

Request access →

Partnerships

Geron (license and collaboration agreement in 2010)

Beyond the preview

Go deeper on Angiochem Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angiochem Inc..

Explore the full profile